Previous 10 | Next 10 |
Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...
Gainers: Obalon Therapeutics (OBLN) +116%, Oncternal Therapeutics (ONCT) +77%, Fate Therapeutics (FATE) +41%, Constellation Pharmaceuticals (CNST) +33%, Nkarta (NKTX) +28%.Losers: scPharmaceuticals (SCPH) -33%, Aptose Biosciences (APTO) -...
scPharmaceuticals (SCPH) slips 38% in premarket in reaction to yet another complete response letter ((CRL)) from the FDA regarding its regarding marketing application for Furoscix (furosemide) for the treatment of worsening heart failure due to congestion.The FDA cited their need to...
scPharmaceuticals (SCPH) -40% on complete response letter from FDA for FUROSCIX.Lyra Therapeutics, Inc. (LYRA) -28% on positive topline results for LANTERN phase 2 randomized controlled study of LYR-210 for the treatment of chronic rhinosinusitis with and without nasal polyps.A...
BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, t...
BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, t...
scPharmaceuticals (SCPH): Q3 GAAP EPS of -$0.33 beats by $0.05.Cash, cash equivalents, restricted cash and investments of $114.5MPress Release For further details see: scPharmaceuticals EPS beats by $0.05
Commercial ization preparedness activities continuing ahead of December 30 PDUFA date for FUROS C IX ® (furosemide injection) for subcutaneous administration Enrolled first patient in FREEDOM-HF Phase 3 clinical trial Projected an...
BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John...
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today provided a business update on FUROSCIX ® , its investigatio...
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f $58.4 million Company to host investor conference call and web...